findmyKOL

Madhu Midathada, MD

Basic profile

Nebraska Hematology-Oncology

ORCIDNone on fileNPI
RegionLincoln, NE · MidwestSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Madhu Midathada is an Oncology physician affiliated with Nebraska Hematology-Oncology. OpenAlex indexes 14 publications with 640 citations (h-index 7).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
14publications

Distinct works indexed by OpenAlex.

640citations

Total citations across indexed works.

7h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
34companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

4004 Pioneer Woods Dr
Lincoln, NE 685067548

Telephone

402-484-4900

Provider last certified this registry record 1 May 2023.

View the NPPES registry record

Industry payments

34 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    42.4%
    Iron, parenteral preparations40.8%
    Ferric carboxymaltose100%
    Part B, office-administered67 patients
    Thrombopoietin Receptor Agonist0.8%
    Romiplostim100%
    Part B, office-administered11 patients

    + 4 more classes in this area

  • Cancer & immunology

    29.2%
    PD-1 inhibitor12.7%
    Pembrolizumab66%Nivolumab34%
    Part B, office-administered27 patients
    CD38-directed Cytolytic Antibody9.6%
    Daratumumab100%
    Part B, office-administered25 patients

    + 11 more classes in this area

  • Metabolism & gastrointestinal

    16.5%
    Substance P/Neurokinin-1 Receptor Antagonist7.9%
    Aprepitant100%
    Part B, office-administered43 patients
    Other antiemetics5.7%
    Fosaprepitant100%
    Part B, office-administered28 patients

    + 6 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”